Gynecologic Oncology

In 1975, Tongji Hospital established Gynecologic Oncology Wards; 2 years later, Gynecologic oncology laboratory was founded. Now, the Gynecologic Oncology Department of Tongji Hospital is the Training Center of the China Gynecological Oncology Group in Central China Area, and the laboratory is now the key lab of Ministry of Education and Hubei Province. The Department equipped with the ThinPrep Cytology Test (TCT) system, the computer-assisted cytological test (CCT) system, and the Colposcope Diagnosis System, loop electrosurgical excision procedure (LEEP) systems, blood lead detector, CO2 incubator, biological microscope, slice flow cytometry, PCR system, laser capture system, high-speed centrifuge, electrophoresis gel analysis system, inverted microscope and microscopic operating system, etc.

The department now has 3 professors, 6 associate professors, 5 attending physicians (with 10 doctoral degrees among them), 23 nurses, 4 technicians, 2 workers and 1 secretary. Professor Ding Ma, the current leader of the department, is one of the most famous clinical experts in China, and also the first Owner of the National Science Foundation for Distinguished Young Scholars of China and the Chief Scientist of 973 Program in the field of Gynecology.  Now he is the dean of the National Key Discipline (Gynecology and Obstetrics), director of Key Laboratory of Ministry of Education and Hubei Province. He is famous in the field of gynecology and cancer research domestically and internationally.

The Department is one of the first institutions that involved in the cancer gene therapy in China. It also focuses on the issues such as tumor transplant and self-control research. The research group keeps the long-term cooperation relationship with Southwestern Medical Center of Dallas, Huston M. D. Anderson Cancer Center, the University of Pittsburgh, and the University of Pennsylvania. The present research involved in the cancer gene therapy and the gene control of metastasis.

Under the leading of Professor Ding Ma, and by efforts of all staff, the department achieved a lot in clinical, scientific research and teaching area in the decade. The department has established “Reproductive function-reserved operations for cervical cancer patients” and “Postoperative Hormone Replacement Therapy for patients with gynecologic carcinoma” projects with smoothly progression. On the same time, involves a multi-center clinical research about the cervical cancer neoadjuvant chemotherapy for reproductive/endocrine function-reserved treatment. The department now undertakes scientific research projects from 973 Program, 863 Program, NSFC and key projects from Hubei Province, gains 6 national or provincial level awards. Many doctors get funds from NSFC and become the talents in the field of gynecological oncology.

The Gynecologic Oncology Department of Tongji Hospital has a group of famous experts and professors, a domestic first-class technical service team, and an international first-class detection method. The Gynecologic Oncology Diagnosis and Treatment Center is clinically experienced at affairs about gynecologic oncology. The Department now equipped with 9 ultrasonic apparatus (including 2 color and 3 3-D ultrasonic apparatus), 2 colposcopes, 2 loop electrosurgical excision procedure (LEEP) systems, 2 set of laparoscopes (Olympus), 2 set of ultrasonic scalpels, a bipolar coagulation system, a ThinPrep Cytology Test equipment, and a Colposcope Diagnosis System.

1. The Gynecologic Oncology Department of Tongji Hospital is the National Training Base for the gynecologic oncologists, and equipped with the ThinPrep Cytology Test (TCT) system, the computer-assisted cytological test (CCT) system, and the Colposcope Diagnosis System. We establish the early cervical cancer screening and diagnosis platform, by which we can standardize the early diagnosis and treatment of the cervical lesions.

2. We develop neoadjuvant chemotherapy for cervical cancer actively, which provides operation opportunities and improves the quality of life for advanced cervical cancer patients. For those early cervical cancer patients, we apply reproductive function-reserved operations actively.

3. We develop standardized comprehensive treatment for all kinds of gynecologic cancers, which reaching the advanced international level and leading the domestic level. We complete nearly 1000 cases of gynecologic oncology operations every year, which including radical hysterectomy, pelvic lymphadenectomy (including aortic lymphadenectomy), and satisfied cytoreductive surgery.

4. On the base of conventional operation, we broaden the application of minimally invasive surgical technique in gynecologic oncology, for example, we apply laparoscopic hysterectomy and bilateral salpingo-oophorectomy, laparoscopic lymphadenectomy in patients with endometrial carcinoma, laparoscopic radical hysterectomy with lymphadenectomy in patients with early cervical cancer.

To develop new clinical techniques, we establish “Reproductive function-reserved operations for cervical cancer patients” and “Postoperative Hormone Replacement Therapy for patients with gynecologic carcinoma” projects with smoothly progression. We now involve a multi-center clinical research about the cervical cancer neoadjuvant chemotherapy for reproductive/endocrine function-reserved treatment.

Our aim is to provide superb medical skills and personalized services for gynecologic carcinoma patients, and we believe our high-quality medical technology provides a solid grantee for the woman’s health.

The Dean of the department is Ding Ma.